Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

1.970 -0.040 (-1.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,660,234
Open 2.070
Bid (Size) 1.980 (10)
Ask (Size) 2.000 (41)
Prev. Close 2.010
Today's Range 1.940 - 2.110
52wk Range 0.1311 - 3.290
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing. 
Via Benzinga

Performance

YTD
+75.9%
+75.9%
1 Month
-10.9%
-10.9%
3 Month
+885.5%
+885.5%
6 Month
+82.4%
+82.4%
1 Year
+129.0%
+129.0%

More News

Read More
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
Via Stocktwits
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Via Benzinga
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
From Vor Biopharma
Via GlobeNewswire
Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Here are the top movers in Monday's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
These stocks have an unusual volume in today's session
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 1.970
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 08/29/25 04:00 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 131.90M
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 132M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.